Menu

Natasha Leskovsek

Of Counsel

I’ve taken my clinical and consulting experience for pharma and biotech companies on regulatory issues and brought them to Cooley’s clients.

+1 202 728 7131
nleskovsek@cooley.com

Natasha Leskovsek advises pharmaceutical, biotechnology, medical device and food/dietary supplement industry clients on US Food and Drug Administration regulatory and clinical development matters. She also conducts regulatory diligence on behalf of entities investing in FDA-regulated companies.

Download full bio

Experience

  • Forty Seven Agrees to Sell to Gilead for $4.9 Billion  

  • Reata Pharmaceuticals – $505 Million Follow-On Offering 

  • argenx – $557 Million Follow-On Offering 

  • Synthorx to Sell to Sanofi for $2.5 Billion 

  • Avidity Biosciences – $100 Million Series C 

  • View all

Practices & Industries
Passions

    Providing practical compliance solutions at the intersection of science and regulation

Education

  • Georgetown University Law Center
    JD, 1996

  • University of Maryland, College Park
    MBA, 1991

  • University of Maryland, College Park
    MPM, 1991

  • University of Maryland, Baltimore
    BSN, 1989

Admissions & Credentials

District of Columbia

Maryland

Media & Insight
Memberships

  • American Health Lawyers Association

  • Food and Drug Law Institute

Contact

+1 202 728 7131 office
+1 202 842 7899 fax
nleskovsek@cooley.com

1299 Pennsylvania Avenue, NW
Suite 700
Washington, DC 20004-2400

Back to top

© 2020 Cooley LLP and Cooley (UK) LLP. All rights reserved.

Cooley® is a registered service mark of Cooley LLP in the United States and European Union as well as certain other jurisdictions.